Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982944 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL2936686 | 0.90 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL22190239 | 0.89 | APP (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL22190246 | 0.89 | APP (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL851166 | 0.87 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL10032066 | 0.86 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL15565880 | 0.85 | MAPT (0.56) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8551794 | 0.85 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8204708 | 0.85 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL5090074 | 0.85 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | ALDH1A1 1683/4885SMN1; SMN2 3578/4885MAPT 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.